Li Zhang1,2, Wim van der Hoek3, Thomas Krafft4, Eva Pilot4, Liselotte van Asten3, Ge Lin5, Shuangsheng Wu1,2, Wei Duan1,2, Peng Yang1,2,6, Quanyi Wang1,2. 1. Institute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control, Beijing, China. 2. Beijing Research Center for Preventive Medicine, Beijing, China. 3. Centre for Infectious Diseases, Epidemiology and Surveillance, National Institute for Public Health and the Environment, Bilthoven, The Netherlands. 4. Department of Health, Ethics & Society, CAPHRI Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. 5. Department of Environmental and Occupational Health, School of Public Health, University of Nevada Las Vegas, Las Vegas, NV, USA. 6. School of Public Health, Capital Medical University, Beijing, China.
Abstract
Background: Since 2007, trivalent inactivated influenza vaccine (TIV) has been provided free-of-charge to primary, middle school and high school students in Beijing. However, there have been few school-based studies on influenza vaccine effectiveness (VE). In this report, we estimated influenza VE against laboratory-confirmed influenza illness among school children in Beijing, China during the 2016-2017 influenza season. Methods: The VE of 2016-2017 TIV against laboratory-confirmed influenza virus infection among school-age children was assessed through a case-control design. Conditional logistic regression was conducted on matched case-control sets to estimate VE. The effect of prior vaccination on current VE was also examined. Results: All 176 samples tested positive for influenza A virus with the positive rate of 55.5%. The average coverage rate of 2016-2017 TIV among students across the 37 schools was 30.6%. The fully adjusted VE of 2016-2017 TIV against laboratory-confirmed influenza was 69% (95% CI: 51 to 81): 60% (95% CI: -15 to 86) for influenza A(H1N1)pdm09 and 73% (95% CI: 52 to 84) for influenza A(H3N2). The overall VE for receipt of 2015-2016 vaccination only, 2016-2017 vaccination only, and vaccinations in both seasons was 46% (95% CI: -5 to 72), 77% (95% CI: 58 to 87), and 57% (95%CI: 17 to 78), respectively.Conclusions: Our study during school outbreaks found that VE of 2016-2017 TIV was moderate against influenza A(H3N2) as well as A(H1N1)pdm09 viruses.
Background: Since 2007, trivalent inactivated influenza vaccine (TIV) has been provided free-of-charge to primary, middle school and high school students in Beijing. However, there have been few school-based studies on influenza vaccine effectiveness (VE). In this report, we estimated influenza VE against laboratory-confirmed influenza illness among school children in Beijing, China during the 2016-2017 influenza season. Methods: The VE of 2016-2017 TIV against laboratory-confirmed influenza virus infection among school-age children was assessed through a case-control design. Conditional logistic regression was conducted on matched case-control sets to estimate VE. The effect of prior vaccination on current VE was also examined. Results: All 176 samples tested positive for influenza A virus with the positive rate of 55.5%. The average coverage rate of 2016-2017 TIV among students across the 37 schools was 30.6%. The fully adjusted VE of 2016-2017 TIV against laboratory-confirmed influenza was 69% (95% CI: 51 to 81): 60% (95% CI: -15 to 86) for influenza A(H1N1)pdm09 and 73% (95% CI: 52 to 84) for influenza A(H3N2). The overall VE for receipt of 2015-2016 vaccination only, 2016-2017 vaccination only, and vaccinations in both seasons was 46% (95% CI: -5 to 72), 77% (95% CI: 58 to 87), and 57% (95%CI: 17 to 78), respectively.Conclusions: Our study during school outbreaks found that VE of 2016-2017 TIV was moderate against influenza A(H3N2) as well as A(H1N1)pdm09 viruses.
Authors: Edward A Belongia; Danuta M Skowronski; Huong Q McLean; Catharine Chambers; Maria E Sundaram; Gaston De Serres Journal: Expert Rev Vaccines Date: 2017-06-09 Impact factor: 5.217
Authors: James C King; Jeffrey J Stoddard; Manjusha J Gaglani; Kristine A Moore; Laurence Magder; Elizabeth McClure; Judith D Rubin; Janet A Englund; Kathleen Neuzil Journal: N Engl J Med Date: 2006-12-14 Impact factor: 91.245
Authors: Danuta M Skowronski; Catharine Chambers; Suzana Sabaiduc; James A Dickinson; Anne-Luise Winter; Gaston De Serres; Steven J Drews; Agatha Jassem; Jonathan B Gubbay; Hugues Charest; Robert Balshaw; Nathalie Bastien; Yan Li; Mel Krajden Journal: Euro Surveill Date: 2017-02-09
Authors: Brendan Flannery; Jessie R Chung; Swathi N Thaker; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Angie Foust; Wendy Sessions; LaShondra Berman; Sarah Spencer; Alicia M Fry Journal: MMWR Morb Mortal Wkly Rep Date: 2017-02-17 Impact factor: 35.301